Insider Transaction Spotlight: Champions Oncology, Inc.

Transaction Overview

On January 10, 2024, Mendelson Daniel Newman, an insider at Champions Oncology, Inc. (Ticker: CSBR), executed a significant purchase of company shares. The transaction involved the acquisition of 2,944 shares of Common Stock at a price of $6.31 per share, resulting in a total transaction value of $18,105.60. This transaction was conducted in a direct ownership capacity, with no equity swaps involved.

Transaction Facts

Insider Profile

Mendelson Daniel Newman has been an insider at Champions Oncology, Inc. since December 12, 2013. He holds a directorial position within the company but is not listed as an officer or a ten percent owner. His historical trading activity in the past year shows a pattern of consistent purchases, with a total of 32 non-derivative transactions recorded.

Historical Trading Context

The latest transaction by Mendelson Daniel Newman comes amidst a period of notable share price volatility for Champions Oncology, Inc. The company's ten-day close price average stood at $5.90, with a recent high of $6.49 and a low of $5.11. Over the past year, the stock has experienced a substantial price change, with a 44.03% increase from the two-hundred-day average and a -28.98% decrease from the fifty-two-week high of $9.88.

Market Data and Financials

Champions Oncology, Inc. operates within the Biotechnology sector of the Healthcare industry. The company's market capitalization is approximately $86,806,048 USD, with a total cash reserve of $4,869,000 USD and total debt of $8,351,000 USD. Its enterprise value is calculated at $90,288,144 USD, reflecting a price-to-sales trailing twelve months ratio of 1.648.

Significance of the Transaction

The recent purchase by Mendelson Daniel Newman aligns with his pattern of acquisitions over the past year, indicating a bullish stance on the company's prospects. The insider's consistent investment in the company's shares may be interpreted as a positive signal of confidence in the company's future performance, especially given the insider's role as a director and his long-standing association with Champions Oncology, Inc.

Other Insider Activities

In the last seven days, there have been no other insider transactions reported, suggesting that Mendelson Daniel Newman's recent purchase is an isolated event rather than part of a broader insider trading trend.

Conclusion

The insider transaction by Mendelson Daniel Newman represents a noteworthy investment in Champions Oncology, Inc. The director's ongoing purchases may serve as a positive indicator to investors, reflecting insider confidence in the company's trajectory. Observers and shareholders alike will be keen to monitor any future insider activities for further insights into the company's internal sentiment.